ASX could hit record high despite mixed bag on Wall Street. US stocks expected to outperform bonds as Fed cuts rates.

This summary of current health news includes FDA approvals for new drugs by Bristol Myers and GE HealthCare, public health ...

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...

NEW YORK -- New York City Mayor Eric Adams pleaded innocent Friday to federal bribery charges, rejecting claims that he accepted overseas travel, campaign cash and other perks from foreign interests ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...